Trial Profile
Platform Therapy (Interferon beta or Glatiramer acetate) Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 Feb 2015 New trial record